What is the recommended vaginal brachytherapy dose for FIGO stage IIb endometrial carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Brachytherapy Dose for FIGO Stage IIB Endometrial Carcinoma

For FIGO stage IIB endometrial carcinoma with gross disease, intrauterine brachytherapy boost after external beam radiotherapy (EBRT) to a cumulative total dose of 75-80 Gy low-dose rate equivalent to the tumor volume (uterus) is recommended. 1

Clinical Context and Treatment Approach

Stage IIB endometrial carcinoma represents disease with cervical stromal involvement, which requires definitive radiation therapy when the patient is medically inoperable or when preoperative therapy is planned.

For Patients with Intact Uterus (Preoperative or Definitive Treatment)

The NCCN guidelines consistently specify that for patients with gross stage IIB disease, the treatment consists of:

  • EBRT to the pelvis: 45-50 Gy for microscopic disease coverage 1
  • Intrauterine brachytherapy boost following EBRT
  • Cumulative total dose: 75-80 Gy low-dose rate (LDR) equivalent prescribed to the tumor volume (uterus) 1

This approach ensures adequate dose to the cervical involvement while treating the entire uterine disease burden.

Radiation Field Coverage

The pelvic EBRT field must target 1:

  • Gross disease
  • Lower common iliac, external iliac, and internal iliac lymph nodes
  • Parametrium
  • Upper vagina
  • Presacral lymph nodes (critical in patients with cervical involvement like stage IIB)

For Post-Hysterectomy Patients (If Surgery Was Performed)

If the patient underwent hysterectomy and stage IIB disease was found pathologically, the brachytherapy approach differs:

After EBRT (45-50 Gy):

  • High-dose rate (HDR) vaginal brachytherapy: 2 fractions of 5-6 Gy prescribed to vaginal mucosa 1
  • Target: upper vagina only
  • Prescription point: vaginal surface or 0.5 cm depth

Vaginal brachytherapy alone (without EBRT) is NOT appropriate for stage IIB disease due to the cervical involvement and higher risk profile.

Important Clinical Considerations

Dose Prescription Specifics

  • Brachytherapy doses are individualized based on clinical situation 1
  • The 75-80 Gy total dose is expressed as LDR equivalent, requiring conversion if using HDR techniques
  • Multiple conformal fields based on CT treatment planning should be used for EBRT 1

Common Pitfall to Avoid

Do not confuse stage IIB (cervical stromal involvement) with early-stage disease. Stage IIB requires more aggressive treatment than stage I disease and should not receive vaginal brachytherapy alone. The cervical involvement necessitates the full 75-80 Gy cumulative dose to the uterine volume when treating definitively.

Quality of Life Consideration

Patients receiving this radiation regimen are at significant risk for vaginal stenosis, which impairs sexual function 1. Vaginal dilator use should begin 2-4 weeks after radiation completion and continue indefinitely to prevent or treat this complication 1.

Treatment Sequencing

The sequencing of EBRT and brachytherapy has not been shown to affect outcomes 2, providing flexibility in treatment planning. However, the standard approach is EBRT followed by brachytherapy boost.

References

1
Guideline

uterine neoplasms. clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2009

2
Guideline

carcinoma of the cervix.

British Journal of Cancer, 2001

Related Questions

After treatment for uterine (endometrial) cancer with a total hysterectomy, are lifelong cancer surveillance screenings required?
What are examples of aggressive endometrial cancers that are limited to a polyp or confined to the endometrium?
What are the FIGO (International Federation of Gynecology and Obstetrics) stage definitions for endometrial, cervical, and ovarian cancers?
What are the surgical guidelines for managing high‑grade endometrial carcinoma?
What is the risk of ovarian and endometrial cancer in women who carry a pathogenic ATM mutation, and what surveillance or risk‑reduction strategies are recommended?
How should I manage a 36-year-old male with atrial fibrillation, a ventricular rate of 120 bpm, and blood pressure of 140/90 mmHg?
Which tests assess a person's body fat and visceral fat, and is there a clinical benefit of performing a dual-energy X-ray absorptiometry (DEXA) scan compared to using a smart weighing scale?
Can desloratadine be used in a patient with primary biliary cholangitis?
Can rhinovirus infection cause severe pneumonia?
In FIGO stage IIB endometrial carcinoma, can treatment be limited to brachytherapy alone?
What is the rationale for treating a patient with normal LDL cholesterol but elevated lipoprotein(a) with statin therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.